News for Mereo BioPharma Group plc (MREO)

PR NewswireNEW YORK, July 22, 2025 NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma

PR NewswireNEW YORK, July 22, 2025 NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharm

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ultragenyx

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (”œMereo” or the ”œC

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (”œUltragenyx” o

PR NewswireNEW YORK, July 17, 2025 NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma

PR NewswireNEW YORK, July 17, 2025 NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharm

Mereo BioPharma Group plc's ORBIT study for setrusumab in osteogenesis imperfecta moves to final analysis by 2025. Click for my MREO update.

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday. The Dow traded up 0.52% to 44,690.5...

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up...

Needham's analyst has adjusted the price target for Mereo BioPharma (MREO), reducing it to $5 from the previous $7, while maintaining a Buy rating on the stock.

U.S. stock futures are showing minimal movement early Thursday, July 10, 2025, as markets digest recent gains and investors await key economic data. The

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI fell sharply in...

On July 10, 2025, Needham analyst Gil Blum released an updated report on Mereo BioPharma Group (MREO), maintaining a 'Buy' rating on the stock. Despite the cons

Ultragenyx (RARE) stock and Mereo (MREO) stock are in selloff after a trial update on thier bone disorder therapy UX143. Read more here.

Summary Ultragenyx Pharmaceutical Inc (RARE) and Mereo BioPharma Group plc have announced the progression of their Phase 3 clinical trials for UX143 (setrusumab

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Tuesday. Shares of Rio Tinto Group RIO fell sharply in today's pr...

Shares of Credo Technology Group Holding Ltd CRDO rose sharply in today's pre-market trading following upbeat quarterly results. The company reported fourth-qu...